Results 11 to 20 of about 19,015 (246)

Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes [PDF]

Biomedicines, 2023
Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist. Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) risk by reducing major adverse cardiovascular events in type 2 ...
Angelo Maria Patti, Rosaria Vincenza Giglio, Alberto Allotta, Andreina Bruno, Tommaso Di Bella, Anca Pantea Stoian, Marcello Ciaccio, Manfredi Rizzo   +7 more
doaj   +3 more sources

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis [PDF]

Cardiovascular Diabetology, 2023
Background Semaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with demonstrated cardiovascular benefits; semaglutide may also have kidney-protective effects.
Peter Rossing, Stephen C. Bain, Heidrun Bosch-Traberg, Ekaterina Sokareva, Hiddo J. L. Heerspink, Søren Rasmussen, Linda G. Mellbin   +6 more
doaj   +2 more sources

Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour Actions [PDF]

Scientia Pharmaceutica
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained considerable attention as a therapeutic agent for type 2 diabetes mellitus and obesity.
Giuseppe Floresta, Davide Arillotta, Valeria Catalani, Gabriele Duccio Papanti Pelletier, John Martin Corkery, Amira Guirguis, Fabrizio Schifano   +6 more
doaj   +4 more sources

Contractile Effects of Semaglutide in the Human Atrium [PDF]

Pharmaceutics
Semaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist. GLP-1R agonists are used to treat type 2 diabetes and obesity. It is currently unknown whether semaglutide can directly increase force of contraction (FOC) in the human heart.
Joachim Neumann, Katarína Hadová, Jan Klimas, Britt Hofmann, Ulrich Gergs   +4 more
doaj   +3 more sources

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes:a substudy of the SUSTAIN 8 randomised, controlled clinical trial [PDF]

, 2020
Aims/hypothesis: Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in a ...
Catarig, Andrei-Mircea, Frias, Juan P., Lausvig, Nanna L., le Roux, Carel W., Lingvay, Ildiko, McCrimmon, Rory, Thielke, Desirée   +6 more
core   +2 more sources

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. [PDF]

, 2018
Altres ajuts: C.M. is supported by the Deutsche Forschungsgemeinschaft (DFG; SFB 894, TRR-219, and Ma 2528/7-1), the German Federal Ministry of Education and Science (BMBF; 01EO1504) and the Corona foundation. J.B.
12, 19, 29, 31 32, 33, 6, Alessandra Dei Cas18, Alexander R. Lyon24, and Stephane Heymans, Antoni Bayes-Genis11, Arantxa Gonza´lez20, Bart Staels30, Christoph Maack1, ChristophWanner35, Dimitrios Farmakis36, Dirk Brutsaert13, Francesco Cosentino16, Frank R. Heinzel4, Frank Ruschitzka37, Gerasimos Filippatos36, Gilles De Keulenaer17, Giuseppe Rosano28, Graham Rena26, Guido Iaccarino, Heiko Bugger14, Heinrich Taegtmeyer9, Ida Gjervold Lunde23, Jean-Sebastien Hulot5, Johann Bauersachs10, Johannes Backs3, Kieran Clarke15, LindaW. van Laake34, Martin Huelsmann21, Michael Lehrke2, Niels P. Riksen27, Nikolaus Marx2, Patrick Rossignol8, Petar Seferovic38, Piero Pollesello25, Rudolf A. de Boer39, Walter J. Paulus7   +40 more
core   +20 more sources

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes [PDF]

, 2016
Background: Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk.
Bain, Stephen C., Baldassarre, Maria Pompea Antonia, Consoli, Agostino, Eliaschewitz, Freddy G., Hansen, Oluf, Holst, Anders G., Jodar, Esteban, Leiter, Lawrence A., Lingvay, Ildiko, Marso, Steven P, Pettersson, Jonas, Rosenstock, Julio, Seufert, Jochen, Vilsboll, Tina, Warren, Mark L., Woo, Vincent   +15 more
core   +2 more sources

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Cardiovascular Diabetology, 2020
Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations.
Mansoor Husain, Stephen C. Bain, Anders Gaarsdal Holst, Thomas Mark, Søren Rasmussen, Ildiko Lingvay   +5 more
doaj   +1 more source

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B., Kothny, Wolfgang, Kozlovski, Plamen, Krum, Henry, Lewsey, James D., Lukashevich, Valentina, McMurray, John J.V., Ponikowski, Piotr   +7 more
core   +2 more sources

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review

Clinical Epidemiology, 2022
Zeyu Xie, Sensen Yang, Weishang Deng, Jinjian Li, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Yang S, Deng W, Li J, Chen J
doaj